An industry veteran reveals that payers, wanting to keep their patient members happy, are highly sensitive to public demand. Pharmaceutical companies can leverage this by generating significant patient and physician interest, which pressures payers into providing more favorable formulary coverage.

The US healthcare system is creating a major bottleneck for GLP-1s. While Medicare is beginning to cover the drugs for seniors, private insurers, who cover two-thirds of Americans, are simultaneously increasing hurdles and dropping coverage, effectively hitting the gas and brakes on a major public health tool.

Many peptides are unlikely to ever receive FDA approval because their simple, easily replicated structures make them commodities. Pharma companies won't fund billion-dollar trials for drugs they can't patent, leaving them in a permanent gray market.

Martin Shkreli claims that from a pharmaceutical development perspective, peptides are often avoided. They possess inherent weaknesses, being more complex than small molecules but less effective than large molecules like antibodies. This makes their recent popularity in biohacking circles ironic to industry insiders.

The critique of the peptide trend often misses that users aren't taking unknown chemicals. Many use compounds like Retatrutide, which is already in Phase 3 clinical trials by Eli Lilly. They are essentially front-running the FDA approval process for drugs that already have substantial clinical backing.

Gaining FDA approval is not the finish line. Many innovative devices fail because they lack a clear reimbursement strategy. Founders must build the economic case for payers and providers in concert with their clinical and regulatory strategy from day one.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

Pharmaceutical companies view the healthcare market as a battle for a patient's total spending capacity. They lobby against non-patentable compounds like peptides not because they have a direct competitor, but because every dollar spent on a compounded peptide is a dollar not spent on one of their high-margin, patented prescription drugs, thus protecting their overall revenue.

Martin Shkreli argues the pharmaceutical industry avoids peptides due to inherent weaknesses like short half-lives, viewing them as the 'worst of both worlds' compared to small molecules or antibodies. This perspective reframes the peptide craze as an elevation of a scientifically challenging and often impractical drug class.